{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:47:02Z","timestamp":1789588022435,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s12325-021-01757-z","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T15:02:27Z","timestamp":1620486147000},"page":"3203-3222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["A Randomized Phase\u00a01 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy"],"prefix":"10.1007","volume":"38","author":[{"given":"Doreen","family":"Barrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanela","family":"Bilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung","family":"Chyung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun M.","family":"Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Iarrobino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kacena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-1426","authenticated-orcid":false,"given":"George","family":"Nomikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Place","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Gordon","family":"Still","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leela","family":"Vrishabhendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"key":"1757_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.24497","volume":"51","author":"WD Arnold","year":"2015","unstructured":"Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51:157\u201367.","journal-title":"Muscle Nerve"},{"key":"1757_CR2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","volume":"8","author":"UR Monani","year":"1999","unstructured":"Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999;8:1177\u201383.","journal-title":"Hum Mol Genet"},{"key":"1757_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155\u201365.","journal-title":"Cell"},{"key":"1757_CR4","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33:831\u201346.","journal-title":"Neurol Clin"},{"key":"1757_CR5","unstructured":"Health and Resources and Services Administration. Newborn screening for spinal muscular atrophy. A summary of the evidence and advisory committee decision. March 13, 2018. https:\/\/www.hrsa.gov\/sites\/default\/files\/hrsa\/advisory-committees\/heritable-disorders\/rusp\/previous-nominations\/sma-consumer-summary.pdf. Accessed Jul 2020."},{"key":"1757_CR6","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3390\/ijms21093297","volume":"21","author":"TH Chen","year":"2020","unstructured":"Chen TH. New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand? Int J Mol Sci. 2020;21:3297.","journal-title":"Int J Mol Sci"},{"key":"1757_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","volume":"15","author":"F Audic","year":"2020","unstructured":"Audic F, de la Banda MGG, Bernoux D, Ramirez-Garcia P, Durigneux J. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet J Rare Dis. 2020;15:148.","journal-title":"Orphanet J Rare Dis"},{"key":"1757_CR8","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","volume":"36","author":"O Dabbous","year":"2019","unstructured":"Dabbous O, Maru B, Jansen JP, et al. Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. Adv Ther. 2019;36:1164\u201376.","journal-title":"Adv Ther"},{"key":"1757_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fneur.2020.00045","volume":"11","author":"N Hensel","year":"2020","unstructured":"Hensel N, Kubinski S, Claus P. The need for SMN-independent treatments of spinal muscular atrophy (SMA) to complement SMN-enhancing drugs. Front Neurol. 2020;11:45.","journal-title":"Front Neurol"},{"key":"1757_CR10","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1038\/s41598-018-20524-9","volume":"8","author":"M Pirruccello-Straub","year":"2018","unstructured":"Pirruccello-Straub M, Jackson J, Wawersik S, et al. Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci Rep. 2018;8:2292.","journal-title":"Sci Rep"},{"key":"1757_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/ng0997-71","volume":"17","author":"L Grobet","year":"1997","unstructured":"Grobet L, Martin LJ, Poncelet D, et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet. 1997;17:71\u20134.","journal-title":"Nat Genet"},{"key":"1757_CR12","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1371\/journal.pgen.0030079","volume":"3","author":"DS Mosher","year":"2007","unstructured":"Mosher DS, Quignon P, Bustamante CD, et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. 2007;3:e79.","journal-title":"PLoS Genet"},{"key":"1757_CR13","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa040933","volume":"350","author":"M Schuelke","year":"2004","unstructured":"Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350:2682\u20138.","journal-title":"N Engl J Med"},{"key":"1757_CR14","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","volume":"45","author":"HQ Han","year":"2013","unstructured":"Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin\/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013;45:2333\u201347.","journal-title":"Int J Biochem Cell Biol"},{"key":"1757_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ana.21338","volume":"63","author":"KR Wagner","year":"2008","unstructured":"Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I\/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63:561\u201371.","journal-title":"Ann Neurol"},{"key":"1757_CR16","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","volume":"3","author":"C Becker","year":"2015","unstructured":"Becker C, Lord SR, Studenski SA, et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2015;3:948\u201357.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1757_CR17","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/jcsm.12331","volume":"9","author":"T Golan","year":"2018","unstructured":"Golan T, Geva R, Richards D, et al. LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. J Cachexia Sarcopenia Muscle. 2018;9:871\u20139.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1757_CR18","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/cen.13601","volume":"88","author":"T Garito","year":"2018","unstructured":"Garito T, Zakaria M, Papanicolaou DA, et al. Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clin Endocrinol (Oxf). 2018;88:908\u201319.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1757_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/mus.25268","volume":"55","author":"C Campbell","year":"2017","unstructured":"Campbell C, McMillan HJ, Mah JK, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017;55:458\u201364.","journal-title":"Muscle Nerve"},{"key":"1757_CR20","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1074\/jbc.M706678200","volume":"283","author":"SB Anderson","year":"2008","unstructured":"Anderson SB, Goldberg AL, Whitman M. Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. J Biol Chem. 2008;283:7027\u201335.","journal-title":"J Biol Chem"},{"key":"1757_CR21","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/hmg\/ddy382","volume":"28","author":"KK Long","year":"2019","unstructured":"Long KK, O\u2019Shea KM, Khairallah RJ, et al. Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Hum Mol Genet. 2019;28:1076\u201389.","journal-title":"Hum Mol Genet"},{"key":"1757_CR22","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, November 27, 2017. U.S. Department of Health and Human Services. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed Jul 2020."},{"key":"1757_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/cpdd.386","volume":"7","author":"I Bhattacharya","year":"2018","unstructured":"Bhattacharya I, Pawlak S, Marraffino S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an antimyostatin monoclonal antibody, in healthy subjects. Clin Pharmacol Drug Dev. 2018;7:484\u201397.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1757_CR24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/mus.26113","volume":"57","author":"CE Glasser","year":"2018","unstructured":"Glasser CE, Gartner MR, Wilson D, Miller B, Sherman ML, Attie K. Locally acting ACE-083 increases muscle volume in healthy volunteers. Muscle Nerve. 2018;57:921\u20136.","journal-title":"Muscle Nerve"},{"key":"1757_CR25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/2472555219860779","volume":"25","author":"CM Cote","year":"2020","unstructured":"Cote CM, Jackson J, Pirruccello-Straub M, Carven GJ, Wawersik S. A sensitive and selective immunoassay for the quantitation of serum latent myostatin after in vivo administration of SRK-015, a selective inhibitor of myostatin activation. SLAS Discov. 2020;25:95\u2013103.","journal-title":"SLAS Discov"},{"key":"1757_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/0167-5699(95)80161-8","volume":"16","author":"B Klein","year":"1995","unstructured":"Klein B, Brailly H. Cytokine-binding proteins: stimulating antagonists. Immunol Today. 1995;16:216\u201320.","journal-title":"Immunol Today"},{"key":"1757_CR27","doi-asserted-by":"crossref","unstructured":"Place A, Scholar Rock SRK-015 Team. A phase 2 study to evaluate the efficacy and safety of SRK-015 in patients with later-onset spinal muscular atrophy (TOPAZ): an introduction. Presented at the 2nd International Scientific & Clinical Congress on Spinal Muscular Atrophy. Evry, France, February 5\u20137, 2020.","DOI":"10.1212\/WNL.94.15_supplement.4534"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01757-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01757-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01757-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T12:36:00Z","timestamp":1725021360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01757-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,8]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1757"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01757-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,8]]},"assertion":[{"value":"15 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}